The use of cefotaxime for the treatment of common infections: In vitro, pharmacokinetic and clinical considerations

Journal of Chemotherapy

Volumn 9, Issue SUPPL. 2, 1997, Pages 5-18

  Wilson, W R ^a   Bouza, E ^b   Lode, H ^c   Mouton, Y ^d  

^a MAYO CLINIC   (United States)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c MARTIN LUTHER KRANKENHAUS   (Germany)

^d CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

Cefotaxime; Community acquired infection; Nosocomial infection; Pediatric patients

Indexed keywords

AMOXICILLIN; CEFACLOR; CEFALOTIN; CEFODIZIME; CEFOPERAZONE; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; IMIPENEM; PENICILLIN DERIVATIVE; PENICILLIN G; TEICOPLANIN; VANCOMYCIN;

AGE; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BONE INFECTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; LOWER RESPIRATORY TRACT INFECTION; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA MENINGITIDIS; PNEUMONIA; REVIEW; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; CEFOTAXIME; CEPHALOSPORINS; CHILD; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 0030848928     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Weidermann B, Dietz H. Cefotaxime unchanged antibacterial activity over the years? Diagn Microbiol Infect Dis 1995; 22: 5-12.
2. Neu HC. Cephalosporins - cefotaxime 10 years later, a major drug with continued use. Infection 1991; 19 (Suppl 6): 309-315.
3. Yeo SF, Chiew YF, Fung CP. Susceptibility of Haemophilus influenzae isolates with known resistance mechanisms to five cephalosporins. Chemotherapy 1996, 42: 85-89.
4. Blondeau JM, Yaschuk Y. In vitro activities of ciprofloxacin, cefotaxime, ceftriaxone, chloramphenicol, and rifampin against fully susceptible and moderately penicillin- resistant Neisseria meningitidis. Antimicrob Agents Chemother 1995; 39: 2577-2579.
5. Doern GV. The in vitro activity of cefotaxime versus bacteria involved in selected infections of hospitalized patients outside of the intensive care unit. Diagn Microbiol Infect Dis 1995; 22: 13-17.
6. Klugman KP, Saunders J. In vitro susceptibility of penicillin-susceptible and penicillin-resistant pneumococci to parenteral third- and fourth-generation cephalosporins. 6th International Congress of Infectious Diseases, Prague, 1994; Poster No. PCS 40.
7. Jones RN. The antimicrobial activity of cefotaxime: comparative multinational hospital isolate surveys covering 15 years. Infection 1994; 22 (Suppl 3): 152-157.
8. Jette LP, Ringuette L, Dascal A, Lapointe J-R, Turgeon P. Pneumococcal resistance to antimicrobial agents in the province of Quebec, Canada. J Clin Microbiol 1994; 32:2572-2575.
9. Barry AL, Novick WJ. Susceptibility of contemporary U.S. isolates of Streptococcus pneumoniae to cefotaxime, cefpirome, ceftriaxone and ceftazidime. 6th International Congress for Infectious Diseases, Prague, 1994; Abstract PCS 56.
10. Johnson AP, Speller DCE, Patel BC. Sensitivity to cefotaxime of pneumococci isolated in the U.K. J Antimicrob Chemother 1995; 38: 443-446.
11. Bouza E, Munoz P. Penicillin-resistant pneumococci in adult disease with special reference to AIDS patients. Microbiol Drug Res 1995; 1 (1): 9-28.
12. Patel KB, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn Microbiol Infect Dis 1995; 22: 49-55.
13. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96.
14. Neu HC. Antibacterial activity of desacetylcefotaxime alone and in combination with cefotaxime. Rev Infect Dis 1982; 4 (Suppl 4): S374-S378.
15. Jones RN. Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity. A review. Diagn Microbiol Infect Dis 1995; 22: 19-33.
16. Jones RN. A review of cephalosporin metabolism: a lesson to be learned for future chemotherapy. Diagn Microbiol Infect Dis 1989; 12: 25-31.
17. Turnidge JD. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime. Diagn Microbiol Infect Dis 1995; 22: 57-69.
18. Bundtzen RW, Gerber AU, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981; 3: 28-37.
19. McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135: 217-223.
20. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 (Suppl C): 29-40.
21. Craig WA, Gudmundsson S. The postantibiotic effect. In: Lorian V. (ed.) Antibiotics in Laboratory Medicine, 3rd edition. Baltimore: Williams and Wilkins, 1991: 403-431.
22. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993; 31 (Suppl D): 249-258.
23. Bartlett JG, Mundy LM. Community acquired pneumonia. N Engl J Med 1995; 333 (24): 1618-1624.
24. Leedom JM. Pneumonia: Patient profiles, choice of empiric therapy, and the place of third generation cephalosporins. Diagn Microbiol Infect Dis 1991; 15: 57-65.
25. British Thoracic Society, London. Guidelines for the management of CAP in adults admitted to hospital. Br J Hosp Med 1993; 49: 346-352.
26. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with CAP: Diagnosis, assessment ot severity and initial antimicrobial therapy. Am Rev Resp Dis 1993; 146: 1418-1426.
27. Garber GE, Auger P, Chan RMT, Conley JM. A multicenter open comparative study of patenteral cefotaxime and ceftriaxone in the treatment of nosocomial lower respiratory tract infections. Diagn Microbiol Infect Dis 1992; 15: 85-88.
28. Dansey RD, Jacka PJ, Strachan SA, Hay M. Comparison of cefotaxime and ceftriaxone given intramuscularly 12-hourly for CAP. Diagn Microbiol Inf Dis 1992; 15: 81-84.
29. Dollman AL, Bataglia A, DeLuca M. Comparison of cefotaxime (1 g bid) and ceftriaxone (1 g qd) in the treatment of CAP in hospitalised adult patients. International Congress of Chemotherapy, Stockholm, 1995.
30. Linares J, Alonso T, Perez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992; 30: 279-288.
31. Yoshida R, Kakl M, Kohno S, et al. Trends in antimicrobial resistance of Streptococcus pneumoniae in Japan. Antimicrob Agents Chemother 1995; 39: 1196-1198.
32. Hedlund J, Svenson SB, Kalin M, et al. Incidence, capsular types, and antibiotic susceptibility of invasive Streptococcus pneumoniae in Sweden. Clin Infect Dis 1995; 21: 948-953.
33. Reinert RR, Queck A, Kaufhold A, Kresken M. Antimicrobial resistance and type distribution of Streptococcus pneumoniae isolates causing systemic infections in Germany. Clin Infect Dis 1995; 21: 1398-1401.
34. Verhagen J, Glupczynski Y, Verbist L, et al. Capsular types and antibiotic susceptibility of pneumococci isolated from patients in Belgium with serious infections. 1980-1993. Clin Infect Dis 1995; 20: 1339-1345.
35. Marchese A, Debbia EA, Arvigo A, Pesce A, Schito GC. Susceptibility of Streptococcus pneumoniae strains isolated in Italy to penicillin and ten other antibiotics. J Antimicrob Chemother 1995; 36: 833-837.
36. Pallares R, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474-480.
37. Annual Report of the Hungarian Public Health Network. National Institutes of Hygiene, 1992; Budapest.
38. Kam KM, Luey KY, Fung SM, Yiu PP, Harden TJ, Cheung MM. Emergence of multiple-antibiotic-resistant Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1995; 39: 2667-2670.
39. Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146: 920-923.
40. Dawson S, Pallett A, Davidson A, Tuck A. Outbreak of multiresistant pneumococci. J Hosp Infect 1992; 22: 328-329.
41. Haas DW, Stratton CW, Griffin JP, Weeks L, Aus SC. Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae. Clin Infect Dis 1994; 20: 671-676.
42. Frémaux A, Sissia G, Geslin P. In vitro antibacterial activity of cefotaxime, cefpirome and four other beta-lactam antibiotics against penicillin-resistant Streptococcus pneumoniae. 6th International Congress for Infectious Diseases, Prague, 1994; Abstract PCS 26.
43. Rubinstein E, Rubenstein B. Treatment of severe infections caused by penicillin-resistant pneumococci. A role for third generation cephalosporins. Infection 1994; 22 (Suppl 3): 161-166.
44. Geslin P, Frémaux A, Sissia G, Spicq C, Aberrane S. Epidemiologie de la resistance aux antibiotiques de Streptococcus pneumoniae en France. Reseau national de surveillance (1984-1993). Med Mal Infect 1994; 24 (Special): 948-961.
45. Linares J, Pallares R, Alonso T, et al. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis 1992; 15(1): 99-105.
46. Spangler SK, Jacobs MR, Appelbaum PC. Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766) and other oral and parenteral agents against 203 penicillin-susceptible and resistant pneumococci. Antimicrob Agents Chemother 1996; 40 (2): 481-484.
47. Lister PD. Multiply resistant Pneumococcus: therapeutic problems in the management of serious infections. Eur J Microbiol Infect Dis 1995; 14 (Suppl): S18-S25.
48. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC. Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother 1996; 40: 1973-1976.
49. Dhoyen N, Goldstein FW, Kitzis MD, et al. Spontaneous resistant mutants of Streptococcus pneumoniae (Sp) isolated after selection on cefotaxime (CTX) and ccfixime (CFM). 6th International Congress for Infectious Diseases, Prague, 1994.
50. Baquero F, Morosini MI, Negri MC. Beta-lactam-resistant Streptococcus pneumoniae: new bacterial pathogen? Eur Resp Rev 1994; 4: 316-320.
51. Jones RN, Erwin ME, Bale M. New insights into the activity of third-generation cephalosporins against pneumonia-causing bacteria. Diagn Microb Inf Dis 1992; 15: 73-80.
52. 1, in the treatment of nosocomial lower respiratory tract infections in ICU patients. Eur Resp Rev 1994; 4 (22): 321-328.
53. Keller C. Prospective evaluation of twice-daily cefotaxime in the treatment of hospitalized patients with severe infections. Diagn Microbiol Infect Dis 1995; 22: 159-161.
54. Cade JF, Presneill J, Keighley C, Sinickas V. Efficacy of a low dose of cefotaxime in serious chest infections. Chest 1992; 101: 1393-1398.
55. Dajani AS. Cefotaxime use in pediatric infections. Diagn Microbiol Infect Dis 1995; 22: 105-110.
56. Martindale (30th Edition) Reynolds JEF (ed.). London, The Pharmaceutical Press, 1993: 91-92, 131.
57. Hart CA, Cuevas LE, Marzouk O, Thomson APJ, Sills J. Management of bacterial meningitis. J Antimicrob Chemother 1993; 32 (Suppl A): 49-59.
58. Odio CM. Cefotaxime for treatment of neonatal sepsis and meningitis. Diagn Microbiol Infect Dis 1995; 22: 111-117.
59. Lewis DA, Reeves DS. Antibiotics at the extremes of age: choices and constraints. J Antimicrob Chemother 1994; 34 (Suppl A): 11-18.
60. Aujard Y, Brion F, Jacqz-Aigain E, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in the newborn. Diagn Microbiol Infect Dis 1989; 12: 87-91.
61. Jacobs RF, Kearns GK. Cefotaxime and desacetylcefotaxime in neonates and children: a review of microbiologic, pharmacokinetic and clinical experience. Diagn Microbiol Infect Dis 1989; 12: 93-99.
62. Feldstein TJ, Uden DL, Larson TA. Cefotaxime for treatment of Gram-negative bacterial meningitis in infants and children. Pediat Infect Dis J 1987; 6: 471-475.
63. Helwig HF. Cefotaxime monotherapy of bacterial meningitis caused by Gram-positive pathogens. Infection 1985; 13 (Suppl 1): 62-67.
64. Helwig H, Schegel P. Cefotaxim monotherapie der bakteriallen meningitis im kindesalter. Monatsschrift für Kinderheilkunde 1986; 134: 733-737.
65. Lecour H, Seara A, Miranda AM, Cordeiro J. Cefotaxime in pneumococcal meningitis. Infection 1985; 13 (Suppl 1): 73-75.
66. Sow A. Cefotaxime treatment of meningitis in children. J Antimicrob Chemother 1984; 14 (Suppl B): 191-194.
67. Jones RN. The injectable cephalosporins in the treatment of serious infections. Infection 1994; 22 (Suppl 3): 182-183.
68. Stratton CW, Aldridge KE, Gelfand M. In vitro killing of penicillin-susceptible, intermediate, and resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone and ceftizoxime. A comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagn Microbiol Infect Dis 1995; 22: 35-42.
69. Frémaux A, Sissia G, Geslin P. Killing kinetics of cefpirome and cefotaxime alone and in combination with fosfomycin, rifampicin and vancomycin against penicillin-resistant Streptococcus pneumoniae isolated from cerebrospinal fluid. 6th International Congress for Infectious Diseases, Prague, 1994; Abstract PCS 27.
70. Cassellas JM, Tome G, Goldberg M, Bernabo JG. The antimicrobial susceptibility of Streptococcus pneumoniae strains isolated in Argentina to ampicillin and 12 cephalosporins. 6th International Congress for Infectious Diseases, Prague, 1994; Abstract PCS 13.
71. Klugman KP. Management of antibiotic-resistant pneumococcal infection. J Antimicrob Chemother 1994; 34: 191-193.
72. Jourdan CH, Convert J, Peloux A, Boussaid O, Grando J, Tigaud S. Successful CSF penetration of continuous teicoplanin infusion after failure of continuous vancomycin infusion in three cases of shunt-associated meningitis (In French). Pathol Biol 1996; 44: 389-392.
73. Timmerman C, Hoepelman I, de Hond J, et al. Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections. Infection 1992; 20: 34-37.
74. Ludwig G, Knebel L. Cefotaxime in urinary tract infections - comparative clinical studies with gentamicin and with cefoxitin. J Antimicrob Chemother 1980; 6 (Suppl A): 207-211.
75. Höffler D, Piper C. Cefotaxime and cefuroxime, a controlled therapeutic comparison in urinary tract infections. Pharmatherapeutica 1981; 2: 637-641.
76. Thomson KS, Sanders WE, Sanders CC. U.S.A. resistance patterns among UTI pathogens. J Antimicrob Chemother 1994; 33 (Suppl): 9-15.
77. Amyes SGB, Baird DR, Crook DW, et al. A multicenter study of the in vitro activity of cefotaxime, cefuroxime, ceftazidime, ofloxacin and ciprofloxacin against blood and urinary pathogens. J Antimicrob Chemother 1994; 34: 639-648.
78. Aldridge KE. Cefotaxime in the treatment of staphylococcal infections. Comparison of in vitro and in vivo studies. Diagn Microbiol Infect Dis 1995; 22: 195-201.
79. Jones RN, Barry AL. Antimicrobial activity of ceftriaxone, cefotaxime, desacetylcefotaxime and desacctylcefotaxime/cefotaxime in the presence of human serum. Antimicrob Agents Chemother 1987; 31: 818-822.
80. Stratton WC, Kernodle DS, Eades SC, Weeks LS. Evaluation of cefotaxime alone and in combination with desacetylcefotaxime against strains of Staphylococcus aureus that produce variants of staphylococcal β-lactamase. Diagn Microbiol Infect Dis 1989; 12: 57-65.
81. LeFrock JL, Carr BB. Clinical experience with cefotaxime in the treatment of serious bone and joint infections. Rev Infect Dis 1982; 4 (Suppl): S465-S471.